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Hemopoietic and Survival Studies in Immunosuppressed Mice: AS described in the original proposal, studies to evaluate selected USAMRIID AVS agents for hemopoietic effects and for the ability to nonspeciflcally enhance resistance to ooportunistic infections in immunosuppressed hosts were evaluated by Or. M. L. Patchen at the Armed Forces Radiobiology Research Institute (AFRRI). The ability of various agents to stimulate hemopoiesis at the level of the pluripotent hemopoietic stem cell was evaluated using the endogenous spleen colony-foirming unit assay (E-CFU assay).
In this assay, the hemopoietic stem cell content of an animal is reduced by exposure to a sublethal dose of irradiation. Experimental drugs are administered e7ther before (prophylactic drug treatment) or after (therapeutic drug treatment) the hemopoietic injury and evaluated for the ability to accelerate hemopoletic regeneration.
Increases in E-CFU numbers indicate a drugs's ability to function as a hemopoietic stimulant. The second parameter assayed in studies performed at AFRRI was the ability of the same selected AVG agents to prophylactically or therapeutically enhance survival in severely irradiated mice. Since following radiation doses such as those used in these experiments, death results from opportunistic pathogens, these studies provide an indication of the ability of an agent to enhance nonspecific resistance in an immunocompromised host.
During the first year, of this contract 14 USAMRIID AVS agents were evaluated for these parameters.
Results of these studies are summarized in the following two tables and four figures. The most effective agents, taking both prophylactic and therapeutic efficacy Into account were Xerosin, AVS 2776, and AVS 2777. In our initial proposal we had stated that we were interested in developing general and specific immunopotentiators. Earlier data had shown that injection of mice with goat anti-IgD antibodies leads to a. the appearance of T-lymphocytes bearing receptors for the Fc portion of IgD and b. increase of serum IgD levels; furthermore, injection of IgD antibodies to mice have a general immunopotentiating effect. We hypothesized that we could produce monoclonal IgD antibodies with defined specificities which could be injected into mice and enhance specifically the response to a specific antigen. We injected mice with goat-anti-IgD antibodies and we fused their spleen cells with a myeloma partner and screened for IgD production. During the initial 6 months of the proposal we were able to produce 6 monoclonal IgD antibodies. None of these has specificity for any of the tested antigens. Slow production of IgD monoclonals was due to delays in training a technician and other technical difficulties. At that time point we started considering alternatives towards the production of immunopotentiating agents. My laboratory is involved in the study of the regulation of B cell function both in normal individuals and in immunocompromised patients. Along these lines we observed that interleukin-4 (IL-4) was capable of inducing the production of IgE by polyclonally stimulated human B cells. We set up a number of experiments to dissect the mechanisms whereby IL-4 leads polyclonally stimulated B cell to the production of IgE. The first task was to find out whether IL-4 can induce human B cells to produce IgE in the absence of other cells (macrophages and T lymphocytes). This was particularly important since IL-4 is known to stimulate T cells. To obtain highly purified human B cells we first subjected the mononuclear cell (MNC) to gradient centrifugation over Sepracell to remove monocytes and treated them with a coctail of monoclonal antibodies, directed against NK, T lymphocytes and macrophages and then rosetted with goatanti-mouse coated magnetic beads, after which the rosettes were magnetically removed. This procedure yields highly purified (> 5%) B cells. Purified B cells were cultured with Epstein-Barr virus (EBV), a demonstrated T-cell independent Polyclonal B cell activator, in the presence or absence of IL-4. Table I presents data from a dose response experiment, which shows that IL-4 enhances the production of IgA, IgG and IgM by purified human B cells cultured in the presence of EBV. In the absence of IL-4, IgE cannot be detected in the supernatants of B cells cultured with EBV. If IL-4 is present in the cultures then significant amounts of IgE are secreted (Table II) .
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To ensure that IgE is produced we stained IL-4 and EBV-treated cells for cytoplasmic IgE. Indeed 10 our to 3750 cells stained positive for IgE. No IgE producing cells could be detected among the cells treated with EBV in the absence of IL-4 (Table III) . had an effect primarily on cell differentiation and immunoglobulin production while it had minimal effect on cell growth (Table IV) . We next determined that IL-4 is needed primarily at the initiation of the cultures. Cells cultured with EBV without IL-4 for four days and then with IL4 up to 24 days failed to produce IgE (Fig. 1) . Cells had to be cultured with EBV and IL-4 for at least 18 days before IL-4 could be detected (Fig. 2) .
In the course of these experiments we attempted to define the optimum dosage of IL-4 needed for the production of IgE. One complete experiment, presented in Fig. 3 , indicates that the dose response curve is bimodal with one peak at 33 Units or IL-4 and another at 1000 units of IL-4 per ml. We have concluded at this point that IL-4 is able to induce polyclonally activated human B cells to produce IgE.
These experiments are of utmost biological significance; IgE is the main immunoglobulin involved in the defense of organisms against parasitic infections and also in the development of allergic reactions. Little is known about the regulation of the production of IgE by humans. Our in vitro system demonstrates that human B cells can be induced to produce IgE. Our short term goals are to better determine the biology of IgE induction by IL-4. We wish to show that IL-4 has its effect on B cells directly and not through substances secreted by B cells which have been activated by EBV and/or IL-4. Next we want to see whether IL-4 causes IgM+IgD + B cells to switch to IgE producing cells or the expansion of IgE+ cells. Furthermore, we wish to examine whether B cell surface molecules, besides surface Ig, may participate in the induction o-IgE production by IL-4. In the long run we wish to examine the effect of IL-4 and other lymphokines in the regulation of the response of human cells to parasites. 
